Shilpa Medicare Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Shilpa Medicare Ltd trades at ₹620, in a confirmed uptrend and 13 weeks into that stage. That is +42.4% against its own 200-day average. It sits at 98% of a 52-week range of ₹267 to ₹627. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 27 straight weeks.

Today the stock is in a confirmed uptrend — week 13 of stage 2, confirmed. At ₹620 it trades +42.4% versus its 200-day average and sits at 98% of its 52-week range (₹267–₹627).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +182% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 27 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 67th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Shilpa Medicare Ltd trades at 50.8× P/E, mid-range by its own standards (67th percentile). Its long-run median P/E is 41.8×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 50.8× is mid-range by its own standards (67th percentile), against a long-run median of 41.8× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +211.0% against a +35.5% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +15.4%/yr price move, ~+13.8%/yr came from earnings growth and ~+1.6 pp from the multiple (expanding); over 10y, of the +7.8%/yr price move, ~+5.7%/yr came from earnings growth and ~+2.1 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Shilpa Medicare Ltd reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 11.0% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on partial evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

65.5/100 — rank 6 of 24 in Pharma - API & CRAMS · 93% evidence confidence

Shilpa Medicare Ltd scores 65.5 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 6. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 27.5 + 13.1 + 5.6 + 19.3 = 65.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Shilpa Medicare Ltd reported ₹437 Cr of revenue in the Mar 26 quarter, +32.0% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 7.9% a year. The last full year, FY26, came in at ₹1,539 Cr. The last four reported quarters add to ₹1,538 Cr.

Shilpa Medicare Ltd reported ₹437 Cr of revenue in the Mar 26 quarter, +32.0% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 7.9% a year. The last full year, FY26, came in at ₹1,539 Cr. The last four reported quarters add to ₹1,538 Cr.

FY26 revenue came in at ₹1,539 Cr (+20.1% on the year), capping 10 years at 7.9% compound. The latest quarter (Mar 26) printed ₹437 Cr, +32.0% year on year — the 11th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +19.4% growth against the decade's 7.9% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +19.5% over the last 4 quarters against +15.5%/yr over the last 8 — accelerating; TTM profit +208.9% vs +176.1%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 27.0% this quarter (+3.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Shilpa Medicare Ltd's operating margin is 27.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 9.0% to 28.0%. The current quarter sits inside that band.

Shilpa Medicare Ltd's operating margin is 27.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 9.0% to 28.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 27.0%, +3.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–28.0%, and FY26's 28.0% is the top of that band — a record year.

Why the margin moved: operating margin went +3.4 pp year on year while gross margin went −0.9 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

→ Margins held — did that reach the bottom line? Next: profit +620.0% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Shilpa Medicare Ltd earned ₹108 Cr of net profit in the Mar 26 quarter, +620.0% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹243 Cr. The 10-year compound rate is 9.4%. That is 24.7% of the quarter's revenue. The same quarter a year earlier earned ₹15.0 Cr.

Shilpa Medicare Ltd earned ₹108 Cr of net profit in the Mar 26 quarter, +620.0% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹243 Cr. The 10-year compound rate is 9.4%. That is 24.7% of the quarter's revenue. The same quarter a year earlier earned ₹15.0 Cr.

Mar 26 profit was ₹108 Cr, +620.0% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹243 Cr (+211.5%), and the 10-year compound rate is 9.4%.

Why profit moved: revenue contributed +32.0% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +260.2% vs revenue +19.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 173% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 173% of Shilpa Medicare Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹342 Cr of operating cash against ₹243 Cr of profit. After ₹357 Cr of capital spending, ₹−15.0 Cr was left as free cash.

FY26: operating cash of ₹342 Cr against reported profit of ₹243 Cr, leaving free cash of ₹−15.0 Cr after ₹357 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 173% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 173%: the cash cycle tightened 124 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 2.3× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹795 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Shilpa Medicare Ltd's cash conversion cycle runs 301 days in FY26, down from 425 days in FY21. Capital spending ran ₹795 Cr over the last 3 years. At FY26 sales of ₹1,539 Cr each day of that cycle holds about ₹4.2 Cr, so roughly ₹1,269 Cr sits inside the business at any moment.

FY26: debtors at 123 days, inventory at 291 days — roughly 9.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 301 days, tighter than FY21's 425.

The full loop: cash goes out to suppliers and production on day 0; stock waits 291 days to sell; customers pay about 123 days after that; and suppliers themselves are paid at 113 days — netting out to the 301-day cycle.

In money terms: at FY26 sales of ₹1,539 Cr, each day of the cycle holds about ₹4.2 Cr — so the 301-day loop keeps roughly ₹1,269 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹795 Cr over the last 3 fiscal years against ₹341 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹431 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 11% and the ROIC − WACC spread is −3.6 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Shilpa Medicare Ltd earns a ROCE of 11% in FY26. That is up from a trough of 1% in FY23. Return on invested capital clears the cost of that capital by −3.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 15.8% net margin on 0.42× asset turns.

FY26 ROCE is 11%, recovered from a FY23 trough of 1% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 15.8% net margin × 0.42× asset turns × 1.43× balance-sheet leverage ≈ 9.5% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 8.4% − 12.0% = a −3.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.25.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Shilpa Medicare Ltd carries total debt of ₹660 Cr against shareholder equity of ₹2,591 Cr as of Mar 26, a debt-to-equity of 0.25 — effectively unlevered. On the annual view that ratio went from 0.38 in FY22 to 0.25 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹660 Cr against shareholder equity of ₹2,591 Cr — a debt-to-equity of 0.25. On the annual view, debt-to-equity went from 0.38 (FY22) to 0.25 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Promoters cut 4.3 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 4.3 points of Shilpa Medicare Ltd over 8 quarters, the biggest move on the register. That takes promoters to 40.1% of the company. Foreign institutions moved +2.3 points over the same window, to 11.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −4.3 points over 8 quarters to 40.1%; Foreign institutions: +2.3 points over 8 quarters to 11.4%; Domestic institutions: +0.4 points over 8 quarters to 8.1%.

🚨 Why the register moved: promoters drove it (−4.3 points), absorbed on the other side by foreign institutions (+2.3 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Shilpa Medicare Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions